<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01028924</url>
  </required_header>
  <id_info>
    <org_study_id>TE-1777-102-EC</org_study_id>
    <nct_id>NCT01028924</nct_id>
  </id_info>
  <brief_title>Effects of Teduglutide on Cardiac Repolarisation and Conduction in Healthy Male and Female Volunteers</brief_title>
  <official_title>A Randomised, 4-period, Placebo and Active-controlled, Single-dose, Change-over Trial to Evaluate the Effects of Teduglutide on Cardiac Repolarisation and Conduction in Healthy Male and Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nycomed</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nycomed</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to investigate if teduglutide has an effect on cardiac
      repolarisation (QT, QTc interval). Secondary objectives are the investigation of possible
      effects on heart rate and cardiac conduction (RR and PR intervals, QRS duration),
      pharmacokinetics and safety and tolerability in healthy subjects, and to determine the effect
      of the positive control, moxifloxacin, for sensitivity analysis. The trial will consist of a
      screening and a treatment phase of four treatment periods. There is a washout period of at
      least 7 days and 4 weeks at maximum between administrations. The expected total trial
      duration for the individual subject will be about 7 weeks (maximum 17) weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ECG measurement/assessment to determine the effect of a single dose of teduglutide on cardiac repolarisation (QT, QTc interval).</measure>
    <time_frame>until 24 h post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ECG measurement/assessment to determine the effect of a single dose of a positive control, moxifloxacin, on cardiac repolarisation, heart rate, and conduction</measure>
    <time_frame>until 24 h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG measurement/assessment to determine the effect of a single dose of teduglutide on heart rate and cardiac conduction (RR and PR intervals, QRS duration)</measure>
    <time_frame>until 24 h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK blood samples to investigate pharmacokinetics of teduglutide in plasma</measure>
    <time_frame>until 24 h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK blood samples to explore the concentration effect relationship on QT/QTc intervals</measure>
    <time_frame>until 24 h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG measurement/assessment and PK blood samples to investigate safety and tolerability of teduglutide</measure>
    <time_frame>within 14 days after trial medication administration</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Teduglutide 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A, subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Teduglutide 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment B, subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400 mg, oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teduglutide</intervention_name>
    <description>subcutaneous (SC), single dose</description>
    <arm_group_label>Teduglutide 5 mg</arm_group_label>
    <arm_group_label>Teduglutide 20 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Moxifloxacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female volunteers

          -  Normal body weight (body mass index within â‰¥18 and 29 kg/m2 (inclusive) and a body
             weight &gt;50 kg (females) and &gt;60 kg (males).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nycomed GmbH</name>
      <address>
        <city>Konstanz</city>
        <zip>78467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2009</study_first_submitted>
  <study_first_submitted_qc>December 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2009</study_first_posted>
  <last_update_submitted>May 4, 2012</last_update_submitted>
  <last_update_submitted_qc>May 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2012</last_update_posted>
  <responsible_party>
    <name_title>Head of Exploratory Clinical Development</name_title>
    <organization>Nycomed GmbH</organization>
  </responsible_party>
  <keyword>Thorough QTc-Study</keyword>
  <keyword>Short Bowel Syndrome</keyword>
  <keyword>Cardiac safety</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

